West Africa Lassa Fever Vaccine Roadmap
Analysis based on 10 articles · First reported Feb 03, 2026 · Last updated Feb 06, 2026
The launch of the Lassa Fever End-to-End Access Roadmap by the West African Health Organisation (WAHO) and Coalition for Epidemic Preparedness Innovations (CEPI) signals a coordinated effort to address a significant public health threat. This initiative could positively impact pharmaceutical companies involved in vaccine development and manufacturing, as well as healthcare systems in West Africa by reducing the burden of Lassa fever.
The West African Health Organisation (WAHO), with support from the Coalition for Epidemic Preparedness Innovations (CEPI), launched the Lassa Fever End-to-End (E2E) Access Roadmap for West Africa in Abidjan, Ivory Coast. This roadmap aims to ensure fair distribution and access to Lassa fever vaccines, once approved, for high-risk populations across West Africa. The initiative covers all stages from research and development to deployment, emphasizing coordination among governments, manufacturers, funders, and partners to ensure affordability and accessibility. This launch coincides with progress in vaccine research, including a candidate Lassa fever vaccine developed by the University of Oxford entering Phase 1 trials. Nigeria, a high-burden country, is expected to host later trials, with its Nigeria===Nigeria Centre for Disease Control (NCDC) reporting recent cases and deaths. Experts stress that coordinated planning is essential for effective vaccine delivery.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard